Determination of the blood level of mitochondrial DNA for the prediction of pregnancy complication

Skripnichenko Yu.P., Baranov I.I., Vysokikh M.Yu.

1 Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow 117997, Ac. Oparina str. 4, Russia; 2 Diagnostic Center Five, Moscow Healthcare Department, Moscow, Russia; 3 A.N. Belozersky Institute of Physicochemical Biology, Moscow State University, Moscow, Russia
Background. Mitochondria play an important role in the regulation of cellular energy metabolism. During pregnancy, there is a higher mitochondrial functional activity, while at the same time with increased mitochondrial energy generation, there is an elevated production of reactive oxygen species and nitrogen, which is attended by a compensatory rise in the activity of antioxidant protection. In contrast, mitochondrial dysfunctions varying in nature lead to uncontrolled oxidative stress (OS) that damages cells and tissues, which is considered to be one of the leading factors for the pathogenesis of pregnancy complications, such as premature birth (PB), preeclampsia (PE), and fetal growth retardation (FGR). Based on the fact that pregnancy is associated with progressive OS, even in case of its physiological course, it has been suggested that changes in the number of mitochondrial DNA (mtDNA) copies in the blood of pregnant women can serve as a biological marker for the degree of OS induction and for the increased risk of this or that complication during pregnancy.
Objective. To determine plasma mtDNA level in women during physiological and complicated pregnancy.
Subjects and methods. The course of pregnancy and the outcomes of labor were analyzed in 142 were analyzed. According to the results of the analysis, all the examinees were divided into 4 groups: 1) women with physiological pregnancy (PP); 2) those with PB; 3) those with pregnancy complicated by PE; 4) those with pregnancy complicated by FGR. The plasma amount of mtDNA was determined by real-time polymerase chain reaction (PCR). The number of PCR products in the reaction was estimated by the Ct value that was defined as the nth cycle of the reaction, at which fluorescence reaches a predetermined threshold value. The amount of a PCR product of the target gene (mtDNA D-loop) was normalized relative to that of a PCR product of the nuclear β2-microglobulin gene. The copy number of mtDNA was expressed in the standard units 2(-ΔС).
Results and discussion. In complicated pregnancy, the level of mtDNA was found to be higher just in the first trimester. The amount of mtDNA was increased by 49% in pregnant women diagnosed with FGR (p < 0.01), by 48% in those with PB (p < 0.01), and by 25% in those who developed PE (p < 0.05) versus those with PP. The relative level of mtDNA was 153±32, 292±69, 205±84, and 299±101 in the PP, PB, PE, and FGR groups, respectively. ROC analysis showed that the sensitivity and specificity of the assay of blood mtDNA levels in pregnant women in the first trimester in the diagnosis of PB was 100% and 91%, respectively; those in that of PE and FGR were 71% and 64% and 83% and 90%, respectively. The blood mtDNA threshold values associated with an increased risk of PB, PE, and FGR were determined to be 2(-ΔС) ≥209, 2(-ΔС) ≥158, and 2(-ΔС) ≥221, respectively.
Conclusion. The determination of plasma mtDNA levels in the first trimester of pregnancy allows identification of a group of women at an increased risk for PB, PE, and FGR.

Keywords

physiological pregnancy
premature birth
preeclampsia
fetal growth retardation
pregnancy complications
mitochondria
mitochondrial DNA

Supplementary Materials

  1. Table. The level of mtDNA in the blood of women in the first trimester of pregnancy
  2. Fig . 1. Mean mtDNA level in the blood of patients
  3. Fig . 2. ROC curve of the average level of mtDNA in the group (A) - with preterm labor, (B) - with preeclampsia and (B) - with Indra ohm fetal growth retardation compared with women with aphysiological pregnancy

References

1. Palikaras K., Daskalaki I., Markaki M., Tavernarakis N. Mitophagy and age-related pathologies: Development of new therapeutics by targeting mitochondrial turnover. Pharmacol. Ther. 2017; 178: 157-74.

2. Wu F., Tian F.J., Lin Y. Oxidative stress in placenta: health and diseases. Biomed. Res. Int. 2015; 2015: 293271.

3. Мартусевич А.К., Карузин К.А. Окислительный стресс и его роль в формировании дизадаптации и патологии. Биорадикалы и антиоксиданты. 2015; 2(2): 5-14. [Martusevich A.K., Karuzin K.A. Oxidative stress and its role in the formation of disadaptation and pathology. Bioradikaly i antioksidanty. 2015; 2(2): 5-14. (in Russian)]

4. D’Souza V., Chavan-Gautam P., Joshi S. Counteracting oxidative stress in pregnancy through modulation of maternal micronutrients and omega-3 fatty acids Curr. Med. Chem. 2013; 20(37): 4777-83.

5. Duhig K., Chappell L.C., Shennan A.H. Oxidative stress in pregnancy and reproduction. Obstet. Med. 2016; 9(3): 113-6.

6. Genc H., Uzun H., Benian A., Simsek G., Gelisgen R., Madazli R., Güralp O. Evaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk. Arch. Gynecol. Obstet. 2011; 284(6):1367-73.

7. Ghaebi M., Nouri M., Ghasemzadeh A., Farzadi L., Jadidi-Niaragh F., Ahmadi M., Yousefi M. Immune regulatory network in successful pregnancy and reproductive failures. Biomed. Pharmacother. 2017; 88: 61-73.

8. Janssen B.G., Gyselaers W., Byun H.M., Roels H.A., Cuypers A., Baccarelli A.A., Nawrot T.S. Placental mitochondrial DNA and CYP1A1 gene methylation as molecular signatures for tobacco smoke exposure in pregnant women and the relevance for birth weight. J. Transl. Med. 2017; 15(1): 5.

9. Clay Montier L.L., Deng J.J., Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. J. Genet. Genomics. 2009; 36(3): 125-31.

10. Lee H.C., Wei Y.H. Mitochondrial role in life and death of the cell. J. Biomed. Sci. 2000; 7(1): 2-15.

11. Кулида Л.В., Майсина А.И., Перетятко Л.П. Роль митохондриальной дисфункции в развитии патологии плаценты. Мать и дитя в Кузбассе. 2014; 2: 28-31. [Kulida L.V., Maysina A.I., Peretyatko L.P. The role of mitochondrial dysfunction in the development of placental pathology. Mother and child in Kuzbass. 2014; 2: 28-31. (in Russian)]

12. Burnham P., Kim M.S., Agbor-Enoh S., Luikart H., Valantine H.A., Khush K.K., De Vlaminck I. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Sci. Rep. 2016; 6:е27859.

13. Holland O., Dekker Nitert M., Gallo L.A., Vejzovic M., Fisher J.J., Perkins A.V. Placental mitochondrial function and structure in gestational disorders. Placenta. 2017; 54: 2-9.

14. Rudov A., Balduini W., Carloni S., Perrone S., Buonocore G., Albertini M.C. Involvement of miRNAs in placental alterations mediated by oxidative stress. Oxid. Med. Cell. Longev. 2014; 2014: е103068.

15. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr. Pharm. Des. 2014; 20(35): 5507-9.

16. Vyssokikh M.Y., Antonenko Y.N., Lyamzaev K.G., Rokitskaya T.I., Skulachev V.P. Methodology for use of mitochondria-targeted cations in the field of oxidative stress-related research. Methods Mol. Biol. 2015; 1265: 149-59.

17. Wu Y.T., Wu S.B., Wei Y.H. Metabolic reprogramming of human cells in response to oxidative stress: implications in the pathophysiology and therapy of mitochondrial diseases. Curr. Pharm. Des. 2014; 20(35):5510-6.

18. Kuznetsova T., Knez J. Peripheral blood mitochondrial DNA and myocardial function. Adv. Exp. Med. Biol. 2017; 982:347-58.

19. Qiu C., Hevner K., Enquobahrie D.A., Williams M.A. A case-control study of maternal blood mitochondrial DNA copy number and preeclampsia risk. Int. J. Mol. Epidemiol. Genet. 2012; 3(3): 237-44.

20. Colleoni F., Lattuada D., Garretto A., Massari M., Mandò C., Somigliana E., Cetin I. Maternal blood mitochondrial DNA content during normal and intrauterine growth restricted (IUGR) pregnancy. Obstet. Gynecol. 2010; 203(4): 365. e1-6.

21. Hernandez S., Moren C., Catalán-García M., Lopez M., Guitart-Mampel M., Coll O. et al. Mitochondrial toxicity and caspase activation in HIV pregnant women. J. Cell. Mol. Med. 2017; 21(1): 26-34.

22. Williams M.A., Sanchez S.E., Ananth C.V., Hevner K., Qiu C., Enquobahrie D.A. Maternal blood mitochondrial DNA copy number and placental abruption risk: results from a preliminary study. Int. J. Mol. Epidemiol. Genet. 2013;4(2): 120-7.

23. Mandò C., De Palma C., Stampalija T., Anelli G.M., Figus M., Novielli C. et al. Placental mitochondrial content and function in intrauterine growth restriction and preeclampsia. Am. J. Physiol. Endocrinol. Metab. 2014;306(4): E404-13.

Received 09.06.2017

Accepted 23.06.2017

About the Authors

Skripnichenko Yuliya Petrovna, Post-graduate student, Research Center of Obstetrics, Gynecology and Perinatology.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954389492. E-mail: wonder_julia@mail.ru
Baranov Igor Ivanovich, M.D., Ph.D., Professor, the head of organizational and methodical department of the service of the scientific-organizational supply,
Research Center of Obstetrics, Gynecology and Perinatology. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954389492. E-mail: i_baranov@oparina4.ru
Vyssokikh Mikhail Yurievich, PhD, Head of mitochondrial medicine research group, Research Center of Obstetrics, Gynecology and Perinatology.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954387633 E-mail: m_vysokikh@oparina4.ru

For citations: Skripnichenko Yu.P., Baranov I.I., Vysokikh M.Yu. Determination of the blood level of mitochondrial DNA for the prediction of pregnancy complication. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (2): 44-9. (in Russian)
https://dx.doi.org/10.18565/aig.2018.2.44-49

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.